Related Experiment Video
Updated: May 20, 2026
Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
Antibody response to Merkel cell polyomavirus associated with incident lymphoma in the Epilymph case-control study in
Claudia Robles1, Andre Poloczek, Delphine Casabonne
1Unit of Infections and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. crobles@iconcologia.net
Background:
Merkel cell polyomavirus (MCV) has been identified as the cause of Merkel cell carcinoma. The increased incidence of chronic lymphocytic leukemia in Merkel cell cancer cohorts and the lymphotropic properties of the virus suggest a possible viral association with lymphomagenesis. To investigate this potential role, we explored seroreactivity against MCV VP1 capsids within the Epilymph case-control study in Spain.
Methods:
Serum samples from 468 incident lymphomas, categorized into up to 11 entities, and 522 controls frequency matched by age, sex, and recruitment center were tested for MCV antibodies by enzyme immunoassay using Virus-Like-Particles. Adjusted multinomial logistic regression was used to estimate the OR and 95% confidence interval (CI) associated to MCV seroprevalence. Immunosuppressed subjects were excluded.
Results:
MCV seroprevalence was 82% in controls and 85% in lymphoma cases. Among 11 lymphoma categories, MCV seropositivity was significantly higher in diffuse large B-cell lymphomas (DLBCL; 96.4%; OR = 6.1, 95%CI = 1.9-19.8), as compared with controls. MCV prevalences were also higher in follicular lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma, and mature T-cell lymphoma but differences did not reach statistical significance. Lower prevalences were observed for multiple myeloma and other B-cell lymphoma. Exclusion of samples collected after start of treatment did not change the results. In a subset analysis, no significant association was observed between BKV and JCV seroprevalence and DLBCL.
Conclusion:
The association observed between serologic evidence of MCV exposure and DLBCL warrants further research.
Impact:
MCV might be involved in the pathway of DLBCL and other lymphomas.
Insights
Merkel cell polyomavirus (MCV) exposure is linked to diffuse large B-cell lymphoma (DLBCL). Further research is needed to understand MCV's role in DLBCL and other lymphoma development.
Area of Science:
- Oncology
- Virology
- Epidemiology
Background:
- Merkel cell polyomavirus (MCV) causes Merkel cell carcinoma.
- MCV's lymphotropic properties and increased chronic lymphocytic leukemia incidence suggest a role in lymphomagenesis.
Purpose of the Study:
- To investigate the potential role of MCV in lymphomagenesis.
- To explore seroreactivity against MCV VP1 capsids in lymphoma cases and controls.
Main Methods:
- Enzyme immunoassay tested serum samples from 468 lymphoma cases and 522 controls for MCV antibodies.
- Adjusted multinomial logistic regression analyzed MCV seroprevalence associations.
- Immunosuppressed subjects were excluded from the analysis.
Main Results:
- MCV seroprevalence was 82% in controls and 85% in lymphoma cases.
- Significantly higher MCV seropositivity (96.4%) was observed in diffuse large B-cell lymphomas (DLBCL) compared to controls (OR=6.1).
- Elevated MCV prevalence was noted in other lymphomas, but without statistical significance.
Conclusions:
- Serologic evidence of MCV exposure is associated with DLBCL.
- MCV may be involved in the pathogenesis of DLBCL and other lymphoma types, warranting further investigation.
